Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.

Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB.

J Am Coll Cardiol. 2009 Nov 17;54(21):1935-45. doi: 10.1016/j.jacc.2009.05.074. Review.


Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

Keller TT, Squizzato A, Middeldorp S.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005158. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD005158.


Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.

Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators.

JAMA. 2005 Sep 14;294(10):1224-32. Epub 2005 Sep 4.


Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

Squizzato A, Keller T, Romualdi E, Middeldorp S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD005158. doi: 10.1002/14651858.CD005158.pub3. Review.


Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.

Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial.

Circulation. 2004 Sep 7;110(10):1202-8. Epub 2004 Aug 16.


Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation.

JAMA. 2002 Nov 20;288(19):2411-20. Erratum in: JAMA. 2003 Feb 26;289(8):987..


Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators.

N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.


Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.

Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310. Review.


Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.

Biancari F, Airaksinen KE, Lip GY.

J Thorac Cardiovasc Surg. 2012 Mar;143(3):665-675.e4. doi: 10.1016/j.jtcvs.2011.01.069. Epub 2011 Jun 24. Review.


Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.

Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL.

Am J Cardiovasc Drugs. 2007;7(4):289-97.


Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Bhatt DL, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee.

Am Heart J. 2004 Aug;148(2):263-8.


Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, Gabriel S, Jackson JD, Topol EJ, Cohen DJ.

Value Health. 2009 Sep;12(6):872-9. doi: 10.1111/j.1524-4733.2009.00529.x. Epub 2009 Mar 11.


Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.

Gan XD, Wei BZ, Fang D, Fang Q, Li KY, Ding SL, Peng S, Wan J.

Curr Med Res Opin. 2015 Dec;31(12):2313-23. doi: 10.1185/03007995.2015.1098600. Epub 2015 Nov 4. Review.


Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.

Sabatine MS, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CP.

Am Heart J. 2008 May;155(5):910-7. doi: 10.1016/j.ahj.2007.11.020. Epub 2008 Feb 21.


Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.

Sabatine MS, Morrow DA, Dalby A, Pfisterer M, Duris T, Lopez-Sendon J, Murphy SA, Gao R, Antman EM, Braunwald E; ExTRACT-TIMI 25 Investigators.

J Am Coll Cardiol. 2007 Jun 12;49(23):2256-63. Epub 2007 May 25.


Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.

Ntalas IV, Kalantzi KI, Tsoumani ME, Bourdakis A, Charmpas C, Christogiannis Z, Dimoulis N, Draganigos A, Efthimiadis I, Giannakoulas G, Giatrakos I, Giogiakas V, Goumas G, Hatziathanasiou G, Kazakos E, Kipouridis N, Konstantinou S, Milionis H, Nikolopoulos D, Peltekis L, Prokopakis N, Sinteles I, Stroumbis C, Terzoudi K, Thoma M, Tsilias K, Vakalis I, Vardakis K, Vasilakopoulos V, Vemmos K, Voukelatou M, Xaraktsis I, Panagiotakos DB, Goudevenos JA, Tselepis AD.

J Cardiovasc Pharmacol Ther. 2016 Nov;21(6):516-525. Epub 2016 Apr 14.


Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.

Hankey GJ, Hacke W, Easton JD, Johnston SC, Mas JL, Brennan DM, Bhatt DL, Fox KA, Topol EJ; CHARISMA Trial Investigators.

Stroke. 2010 Aug;41(8):1679-83. doi: 10.1161/STROKEAHA.110.586727. Epub 2010 Jul 1.


Critical review of prasugrel for formulary decision makers.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2009 May;15(4):335-43. Review.

Supplemental Content

Support Center